Genus plc (LON:GNS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 2,628.10 and traded as high as GBX 3,175. Genus shares last traded at GBX 3,135, with a volume of 55,584 shares traded.
Analysts Set New Price Targets
A number of equities analysts have weighed in on GNS shares. Berenberg Bank reaffirmed a “buy” rating and set a GBX 3,350 price target on shares of Genus in a research report on Thursday, February 5th. Shore Capital Group reissued a “buy” rating and issued a GBX 3,000 price objective on shares of Genus in a research report on Friday, January 16th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Genus from GBX 3,100 to GBX 3,300 and gave the company a “buy” rating in a research report on Friday, January 16th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of GBX 3,216.67.
View Our Latest Stock Analysis on Genus
Genus Stock Up 0.5%
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
See Also
- Five stocks we like better than Genus
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
